StealthX™ Therapeutics

About Capricor Therapeutics

Capricor Therapeutics is dedicated to developing novel cell and exosome-based therapies for serious rare diseases, with a primary focus on Duchenne muscular dystrophy (DMD). The company's lead asset, Deramiocel, is an allogeneic cardiac-derived cell therapy that has demonstrated significant functional benefits in late-stage clinical trials and is under regulatory review. Capricor's strategy leverages its two synergistic technology platforms—allogeneic cardiosphere-derived cells (CDCs) and the StealthX™ exosome platform—to build a diversified pipeline targeting high-unmet-need conditions.

Therapeutic Areas